1 – 10 of 65
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
Martin de la Fuente, Laura LU ; Westbom-Fremer, Sofia LU
;
Arildsen, Nicolai Skovbjerg
LU
;
Hartman, Linda
LU
;
Malander, Susanne
LU
;
Kannisto, Päivi
LU
;
Måsbäck, Anna
LU
and
Hedenfalk, Ingrid
LU
(2020)
In Virchows Archiv : an international journal of pathology
Mark
- 2019
- Afadin cooperates with Claudin-2 to promote breast cancer metastasis
-
Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method
Arildsen, Nicolai Skovbjerg LU ; Martin de la Fuente, Laura LU ; Måsbäck, Anna LU ; Malander, Susanne LU ; Forslund, Ola LU ; Kannisto, Päivi LU and Hedenfalk, Ingrid LU
(2019)
In Scientific Reports
9(1).
p.1-8
Mark
-
Extracellular lipid loading augments hypoxic paracrine signaling and promotes glioma angiogenesis and macrophage infiltration
Offer, Svenja LU ; Menard, Julien LU ; Enriquez Perez, Julio LU
;
Goncalves De Oliveira, Kelin
LU
;
Indira Chandran, Vineesh
LU
;
Johansson, Maria C
LU
;
Bång-Rudenstam, Anna
LU
;
Siesjö, Peter
LU
;
Ebbesson, Anna
LU
and
Hedenfalk, Ingrid
LU
, et al.
(2019)
In Journal of Experimental & Clinical Cancer Research
38.
Mark
-
Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
Sahin, Irem Durmaz LU ; Jönsson, Jenny Maria LU and Hedenfalk, Ingrid LU
(2019)
In Oncotarget
10(65).
p.6981-6996
Mark
- 2018
- Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
-
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
Matikas, Alexios ; Lövrot, John ; Ramberg, Anna ; Eriksson, Margareta ; Lindsten, Therese ; Lekberg, Tobias ; Hedenfalk, Ingrid LU
;
Loman, Niklas
LU
;
Bergh, Jonas
and
Hatschek, Thomas
, et al.
(2018)
In OncoImmunology
7(9).
Mark
-
Claudin-4 Expression is Associated with Survival in Ovarian Cancer but Not with Chemotherapy Response
Martín De La Fuente, Laura LU ; Malander, Susanne LU ; Hartman, Linda LU ; Jönsson, Jenny Maria LU ; Ebbesson, Anna LU ; Nilbert, Mef LU ; Måsbäck, Anna LU and Hedenfalk, Ingrid LU
(2018)
In International Journal of Gynecological Pathology
37(2).
p.101-109
Mark
-
Ghrelin expression is associated with a favorable outcome in male breast cancer
Grönberg, Malin ; Nilsson, Cecilia ; Markholm, Ida ; Hedenfalk, Ingrid LU
;
Blomqvist, Carl
;
Holmberg, Lars
;
Tiensuu Janson, Eva
and
Fjällskog, Marie Louise
(2018)
In Scientific Reports
8(1).
Mark
- Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer